Tech Beetle briefing FR

Haemonetics Acquires Vivasure Medical for Up to $209.6 Million

Essential brief

Key facts

Haemonetics acquired Vivasure Medical for approximately $209.6 million to expand its vessel closure technology offerings.

Vivasure specializes in minimally invasive vessel closure devices that improve surgical outcomes and patient recovery.

The acquisition supports Haemonetics' strategy to enhance its blood management and surgical product portfolio.

This deal reflects the medical device industry's trend toward consolidation to accelerate innovation and market growth.

Patients and healthcare providers can expect improved vascular closure solutions resulting from this acquisition.

Highlights

Haemonetics acquired Vivasure Medical for approximately $209.6 million to expand its vessel closure technology offerings.

Vivasure specializes in minimally invasive vessel closure devices that improve surgical outcomes and patient recovery.

The acquisition supports Haemonetics' strategy to enhance its blood management and surgical product portfolio.

This deal reflects the medical device industry's trend toward consolidation to accelerate innovation and market growth.

Haemonetics, a global leader in blood management solutions, announced on January 9, 2026, the acquisition of Vivasure Medical, an Ireland-based company specializing in vessel closure technology for minimally invasive procedures. The deal is valued at approximately 185 million euros, which translates to about $209.6 million. This strategic acquisition aims to enhance Haemonetics' product portfolio by integrating Vivasure's innovative technologies that focus on improving vascular closure during surgical interventions.

Vivasure Medical has developed advanced vessel closure devices that are designed to reduce complications and improve patient outcomes in minimally invasive surgeries. These technologies are particularly relevant in procedures that require precise and reliable closure of blood vessels to minimize bleeding and promote faster recovery. By acquiring Vivasure, Haemonetics is positioning itself to meet the growing demand for safer and more effective surgical solutions in the evolving healthcare landscape.

The acquisition aligns with Haemonetics' broader strategy to expand its footprint in the interventional and surgical markets. With the integration of Vivasure's vessel closure technology, Haemonetics can offer a more comprehensive suite of products that address critical needs in blood management and surgical care. This move is expected to drive innovation and provide healthcare providers with enhanced tools to improve patient safety and procedural efficiency.

Financially, the transaction reflects Haemonetics' commitment to investing in cutting-edge medical technologies. The 185 million euro purchase price underscores the value Haemonetics sees in Vivasure's intellectual property, product pipeline, and market potential. The acquisition is anticipated to contribute positively to Haemonetics' revenue growth and profitability in the coming years as the company leverages synergies and expands its market reach.

Overall, the acquisition of Vivasure Medical by Haemonetics represents a significant step in advancing minimally invasive surgical technologies. It highlights the ongoing trend of consolidation in the medical device industry, where established companies acquire innovative startups to accelerate product development and market penetration. For healthcare providers and patients, this development promises access to improved vascular closure solutions that can enhance surgical outcomes and recovery experiences.